{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T01:05:08Z","timestamp":1788743108175,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,2,4]],"date-time":"2019-02-04T00:00:00Z","timestamp":1549238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,2,4]],"date-time":"2019-02-04T00:00:00Z","timestamp":1549238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This study aimed to assess the feasibility of GP73 as a diagnostic marker for liver inflammation and fibrosis in chronic HBV patients with normal or slightly raised ALT (&lt;2 ULN) and to develop models based on GP73 and other biochemical parameters to improve diagnostic accuracy. Serum GP73 levels were analyzed in 220 chronic HBV patients with normal or slightly raised ALT who underwent liver biopsy. The results showed that the area under the receiver operating characteristic (ROC) curve (AUC) was 0.806 for predicting significant liver inflammation (\u2265G2), while it was 0.742 for predicting significant fibrosis (\u2265S2). These results suggest that GP73 has higher diagnostic value for liver inflammation than liver fibrosis. Combining GP73, AST and ALB, as a diagnostic model for predicting significant liver inflammation, resulted in superior diagnostic performance over GP73 alone (AUC value increased from 0.806 to 0.854, z\u2009=\u20092.299, P\u2009=\u20090.021). By applying this diagnostic model, over 80% of chronic HBV patients with normal or slightly raised ALT will be correctly identified and hence avoid delay in diagnosis and treatment. In conclusion, GP73 would be an additional serum marker for predicting liver inflammation and fibrosis in chronic HBV patients with normal or slightly raised ALT.<\/jats:p>","DOI":"10.1038\/s41598-018-36480-3","type":"journal-article","created":{"date-parts":[[2019,2,4]],"date-time":"2019-02-04T11:04:09Z","timestamp":1549278249000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Serum GP73 - An Additional Biochemical Marker for Liver Inflammation in Chronic HBV Infected Patients with Normal or Slightly Raised ALT"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1639-7244","authenticated-orcid":false,"given":"Meijuan","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengju","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingnan","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoman","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LiGuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bishuang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,4]]},"reference":[{"key":"36480_CR1","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.cld.2010.05.007","volume":"14","author":"BJ McMahon","year":"2010","unstructured":"McMahon, B. J. Natural history of chronic hepatitis B. Clin Liver Dis. 14, 381\u201396 (2010).","journal-title":"Clin Liver Dis."},{"issue":"11","key":"36480_CR2","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1743-422X-11-22","volume":"7","author":"A Busca","year":"2014","unstructured":"Busca, A. & Kumar, A. Innate immune responses in hepatitis B virus (HBV) infection. Virol J. 7(11), 22 (2014).","journal-title":"Virol J."},{"key":"36480_CR3","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/S1473-3099(01)00118-9","volume":"1","author":"MF Yuen","year":"2001","unstructured":"Yuen, M. F. & Lai, C. L. Treatment of chronic hepatitis B. Lancet Infect Dis. 1, 232\u201341 (2001).","journal-title":"Lancet Infect Dis."},{"key":"36480_CR4","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver. EASL2017 Clinical Practice Guidelines on the management of hepatitis B virusinfection. J Hepatol. 67, 370\u2013398 (2017).","journal-title":"J Hepatol."},{"key":"36480_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1001\/archinte.166.1.9","volume":"166","author":"SN Wong","year":"2006","unstructured":"Wong, S. N. & Lok, A. S. Treatment of hepatitis B: who, when, and how? Arch InternMed. 166, 9\u201312 (2006).","journal-title":"Arch InternMed."},{"key":"36480_CR6","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1111\/j.1365-2893.2008.00989.x","volume":"15","author":"JY Park","year":"2008","unstructured":"Park, J. Y. et al. High prevalence of significant histology in asymptomatic chronic hepatitis B patients with genotype C and high serum HBV DNA levels. J Viral Hepat. 15, 615\u201321 (2008).","journal-title":"J Viral Hepat."},{"key":"36480_CR7","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1111\/j.1478-3231.2011.02570.x","volume":"31","author":"JY Cheong","year":"2011","unstructured":"Cheong, J. Y. et al. Serum markers for necroinflammatory activity in patients with chronic viral hepatitis and normal or mildly elevated aminotransferase levels. Liver Int. 31, 1352\u20138 (2011).","journal-title":"Liver Int."},{"key":"36480_CR8","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1002\/hep.22742","volume":"49","author":"DC Rockey","year":"2009","unstructured":"Rockey, D. C., Caldwell, S. H., Goodman, Z. D., Nelson, R. C. & Smith, A. D. American Association for the Study of Liver Diseases. Liver biopsy. Hepatology. 49, 1017\u201344 (2009).","journal-title":"Hepatology."},{"key":"36480_CR9","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1002\/hep.22476","volume":"48","author":"MJ Tong","year":"2008","unstructured":"Tong, M. J., Hsien, C., Hsu, L., Sun, H. E. & Blatt, L. M. Treatment recommendations for chronic hepatitis B: an evaluation of current guidelines based on a natural history study in the United States. Hepatology. 48, 1070\u20138 (2008).","journal-title":"Hepatology."},{"key":"36480_CR10","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0378-1119(00)00136-0","volume":"249","author":"RD Kladney","year":"2000","unstructured":"Kladney, R. D. et al. GP73, a novel Golgi-localized protein upregulated by viral infection. Gene. 249, 53\u201365 (2000).","journal-title":"Gene."},{"key":"36480_CR11","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1515\/CCLM.2011.640","volume":"49","author":"X Liu","year":"2011","unstructured":"Liu, X. et al. Golgi protein 73(GP73), a useful serum marker in liver diseases. Clin Chem Lab Med. 49, 1311\u20136 (2011).","journal-title":"Clin Chem Lab Med."},{"key":"36480_CR12","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.jhep.2009.05.029","volume":"51","author":"LM Wright","year":"2009","unstructured":"Wright, L. M. et al. Hepatocyte GP73 expression in Wilson disease. J Hepatol. 51, 557\u201364 (2009).","journal-title":"J Hepatol."},{"key":"36480_CR13","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1111\/j.1440-1746.2011.06733.x","volume":"26","author":"Y Sun","year":"2011","unstructured":"Sun, Y. et al. Increased Golgi protein 73 expression in hepatocellular carcinoma tissue correlates with tumor aggression but not survival. J Gastroenterol Hepatol. 26, 1207\u201312 (2011).","journal-title":"J Gastroenterol Hepatol."},{"key":"36480_CR14","doi-asserted-by":"publisher","first-page":"e659","DOI":"10.1097\/MD.0000000000000659","volume":"94","author":"Z Xu","year":"2015","unstructured":"Xu, Z. et al. Serum Golgi protein 73(GP73) is a diagnostic and prognostic marker of chronic HBV liver disease. Medicine (Baltimore). 94, e659 (2015).","journal-title":"Medicine (Baltimore)."},{"key":"36480_CR15","doi-asserted-by":"publisher","first-page":"2644","DOI":"10.3892\/mmr.2014.3114","volume":"11","author":"Z Xu","year":"2015","unstructured":"Xu, Z. et al. Serum Golgi protein 73 levels and liver pathological grading in cases of chronic hepatitis B. Mol Med Rep. 11, 2644\u201352 (2015).","journal-title":"Mol Med Rep."},{"key":"36480_CR16","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.jhep.2011.11.016","volume":"56","author":"M Sebagh","year":"2012","unstructured":"Sebagh, M. et al. Twenty-year protocol liver biopsies: Invasive but useful for the management of liver recipients. J Hepatol. 56, 840\u20137 (2012).","journal-title":"J Hepatol."},{"key":"36480_CR17","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/j.jhep.2008.01.011","volume":"Suppl 1","author":"F Zoulim","year":"2008","unstructured":"Zoulim, F., Perrillo, R. & Hepatitis, B. Reflections on the current approach toantiviral therapy. J Hepatol. 48 Suppl 1, S2\u201319 (2008).","journal-title":"J Hepatol. 48"},{"key":"36480_CR18","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1053\/jhep.2002.32525","volume":"35","author":"RD Kladney","year":"2002","unstructured":"Kladney, R. D., Cui, X., Bulla, G. A., Brunt, E. M. & Fimmel, C. J. Expression of GP73, a resident Golgi membrane protein, in viral and nonviral liver disease. Hepatology. 35, 1431\u201340 (2002).","journal-title":"Hepatology."},{"key":"36480_CR19","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1111\/j.1572-0241.2004.30572.x","volume":"99","author":"R Iftikhar","year":"2004","unstructured":"Iftikhar, R. et al. Disease- and cell-specific expression of GP73 in human liver disease. Am J Gastroenterol. 99, 1087\u201395 (2004).","journal-title":"Am J Gastroenterol."},{"key":"36480_CR20","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/2045-3701-4-76","volume":"4","author":"F Wang","year":"2014","unstructured":"Wang, F. et al. Epithelium-Specific ETS (ESE)-1 upregulated GP73 expression in hepatocellular carcinoma cells. Cell Biosci. 4, 76 (2014).","journal-title":"Cell Biosci."},{"key":"36480_CR21","doi-asserted-by":"publisher","first-page":"e53862","DOI":"10.1371\/journal.pone.0053862","volume":"8","author":"H Wei","year":"2013","unstructured":"Wei, H. et al. Serum GP73, a marker for evaluating progression in patients with chronic HBV infections. PLoSOne. 8, e53862 (2013).","journal-title":"PLoSOne."},{"key":"36480_CR22","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1111\/liv.13536","volume":"37","author":"Z Cao","year":"2017","unstructured":"Cao, Z. et al. Algorithm of Golgi protein 73 and liver stiffness accurately diagnoses significant fibrosis in chronic HBV infection. Liver Int. 37, 1612\u20131621 (2017).","journal-title":"Liver Int."},{"key":"36480_CR23","first-page":"161","volume":"11","author":"H Liang","year":"2012","unstructured":"Liang, H. et al. Interleukin-6 and oncostatin M are elevated in liver diseasein conjunction with candidate hepatocellular carcinoma biomarker GP73. CancerBiomark. 11, 161\u201371 (2012).","journal-title":"CancerBiomark."},{"key":"36480_CR24","first-page":"34","volume":"2","author":"LM Wright","year":"2009","unstructured":"Wright, L. M., Yong, S., Picken, M. M., Rockey, D. & Fimmel, C. J. Decreased survival and hepato-renal pathology in mice with C-terminally truncated GP73 (GOLPH2). Int J ClinExpPathol. 2, 34\u201347 (2009).","journal-title":"Int J ClinExpPathol."},{"key":"36480_CR25","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1164\/ajrccm.159.4.9712012","volume":"159","author":"A Mignon","year":"1999","unstructured":"Mignon, A. et al. LPS challenge in D-galactosamine-sensitized mice accounts forcaspase-dependent fulminant hepatitis, not for septic shock. Am J RespirCritCare Med. 159, 1308\u201315 (1999).","journal-title":"Am J RespirCritCare Med."},{"key":"36480_CR26","first-page":"71","volume":"98","author":"KD Sekiyama","year":"1994","unstructured":"Sekiyama, K. D., Yoshiba, M. & Thomson, A. W. Circulating proinflammatory cytokines(IL-1 beta, TNF-alpha, and IL-6) and IL-1 receptor antagonist (IL-1Ra) infulminant hepatic failure and acute hepatitis. ClinExpImmunol. 98, 71\u20137 (1994).","journal-title":"ClinExpImmunol."},{"key":"36480_CR27","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.jss.2015.05.060","volume":"199","author":"S Furuya","year":"2015","unstructured":"Furuya, S. et al. Interleukin 17A plays a role in lipopolysaccharide\/D-galactosamine-induced fulminant hepatic injury inmice. J Surg Res. 199, 487\u201393 (2015).","journal-title":"J Surg Res."},{"key":"36480_CR28","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1111\/j.1600-0854.2007.00621.x","volume":"8","author":"C Bachert","year":"2007","unstructured":"Bachert, C., Fimmel, C. & Linstedt, A. D. Endosomal trafficking and proprotein convertase cleavage of cis Golgi protein GP73 produces marker for hepatocellular carcinoma. Traffic. 8, 1415\u201323 (2007).","journal-title":"Traffic."},{"key":"36480_CR29","first-page":"141","volume":"11","author":"W Meijuan","year":"2017","unstructured":"Meijuan, W., Xiaoman, Z. & Zhengju, X. Correlation of GP73 and cytokines before antiviral therapyin patients with chronic hepatitis B. Chin J ExpClin. Infect Dis (Electronic Edition). 11, 141\u2013145 (2017).","journal-title":"Infect Dis (Electronic Edition)."},{"key":"36480_CR30","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/0168-8278(95)80269-X","volume":"22","author":"PJ Scheuer","year":"1995","unstructured":"Scheuer, P. J. The nomenclature of chronic hepatitis: time for a change. J Hepatol. 22, 112\u20134 (1995).","journal-title":"J Hepatol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-36480-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-36480-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-36480-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T05:16:20Z","timestamp":1671254180000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-36480-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,4]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["36480"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-36480-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,4]]},"assertion":[{"value":"22 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"1170"}}